Increased risk of bladder cancer following diagnosis with bladder pain syndrome/interstitial cystitis

Keller, Joseph J.; Chiou, Hung Yi; Lin, Herng Ching

doi:10.1002/nau.22283

Cited by 20 publications

(18 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 4 , 6 , 7 , 8 One study indicated that IC/bladder pain syndrome (BPS) may contribute to bladder cancer (BC) and an increased risk of BC. 9 Therefore, we predicted that there may be an association between miR-214 and IC. Further analysis suggests that miR-214 is able to target Mitofusin 2 (Mfn2) and mediate the fibrosis process.…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Inhibition of microRNA-214 promotes epithelial–mesenchymal transition process and induces interstitial cystitis in postmenopausal women by upregulating Mfn2

Liu¹,

Wen

Jiang³

et al. 2017

Exp Mol Med

View full text Add to dashboard Cite

Our study aims to investigate the roles that microRNA-214 (miR-214) plays in the epithelial mesenchymal transition (EMT) process and the development of interstitial cystitis (IC) in postmenopausal women by targeting Mitofusin 2 (Mfn2). IC bladder tissues and adjacent normal bladder tissues were collected from postmenopausal women. Immunohistochemistry (IHC) staining was conducted. The target relationship between miR-214 and Mfn2 was determined by a dual luciferase reporter gene assay. Adipose-derived mesenchymal stem cells (ADMSCs) were extracted from postmenopausal rats and assigned to the blank, mimics, miR-214 inhibitors, mimics negative control (NC), inhibitors NC, Mfn2 siRNA, miR-214 inhibitors and Mfn2 siRNA groups. Exosomes secreted by transfected ADMSCs were instilled into the bladders of postmenopausal rats. The expression of miR-214 and Mfn2 mRNA and EMT markers was assessed by qRT-PCR and western blotting. It was confirmed that Mfn2 was the target gene of miR-214 in IC. Compared with the normal bladder tissues, miR-214 decreased, but Mfn2 increased in IC bladder tissues. Compared with the blank group, the expression of miR-214 and the expression levels of N-cadherin, Fibronectin, Twist1, Snail and Vimentin mRNA and protein increased, whereas the expression levels of Mfn2, E-cadherin and ZO-1 mRNA and protein decreased in the miR-214 mimics and Mfn2 groups. The expression of MiR-214 and the expression levels of N-cadherin, Fibronectin, Twist1, Snail and Vimentin mRNA and protein decreased, whereas the expression levels of Mfn2, E-cadherin and ZO-1 mRNA and protein increased in the miR-214 inhibitors group. Our findings indicate that the inhibition of miR-214 promotes the EMT process and contributes to bladder wall fibrosis by up-regulating Mfn2, thus leading to the occurrence of IC in postmenopausal women.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Inhibition of microRNA-214 promotes epithelial–mesenchymal transition process and induces interstitial cystitis in postmenopausal women by upregulating Mfn2

Liu¹,

Wen

Jiang³

et al. 2017

Exp Mol Med

View full text Add to dashboard Cite

show abstract

“…This implies a possible role of Notch in bladder pathological conditions, beyond cancer, a hypothesis that could be further investigated in human patient samples. It is important to report that patients with IC are 3 times more likely to develop bladder cancer (46), which could of course relate to chronic inflammation.…”

Section: Discussionmentioning

confidence: 99%

Notch controls urothelial integrity in the mouse bladder

Paraskevopoulou¹,

Bonis²,

Dionellis³

et al. 2020

JCI Insight

View full text Add to dashboard Cite

“…Medical chart summary, medical records of negative urine cytology and urine analysis, and voiding diary are often required for the pre‐review as well. To increase the diagnostic validity of IC, we further ensured that every participant included in the present study group passed the pre‐review to receive a prescription for sodium hyaluronate (Cystistat) . Therefore, there was little possibility for anyone without a clear diagnosis of IC being eligible.…”

Section: Methodsmentioning

confidence: 99%

“…Therefore, there was little possibility for anyone without a clear diagnosis of IC being eligible. The same methods for the enrollment of IC have already been applied in several published studies …”

Section: Methodsmentioning

confidence: 99%

Risks of interstitial cystitis among patients with systemic lupus erythematosus: A population‐based cohort study

Wen

Chuang

et al. 2019

Int J of Urology

View full text Add to dashboard Cite

Abbreviations & Acronyms aHR = adjusted hazard ratio CI = confidence interval DM = diabetes mellitus HTN = hypertension IC = interstitial cystitis ICD-9 CM = International Classification of Diseases-9th Revision-Clinical Modification IR = incidence rate IRR = incidence rate ratio NHI = National Health Insurance NHIRD = National Health Insurance Research Database NTD = New Taiwan Dollars PY = person-year SLE = systemic lupus erythematosus Correspondence: Ming-Ping Objective: To investigate whether the risk of interstitial cystitis increases among the patients with systemic lupus erythematosus. Methods: This was a nationwide population-based cohort study. Data were obtained from the National Health Insurance Research Database in Taiwan. Women aged >18 years newly diagnosed as systemic lupus erythematosus during 2001-2008 were identified as the control group. The comparison included individuals randomly selected from the National Health Insurance Research Database in the year of 2000, by matching one systemic lupus erythematosus participant with eight non-systemic lupus erythematosus participants with sex and age. These participants were followed up until being diagnosed as interstitial cystitis, or the end of 2011. Women diagnosed with lupus cystitis were excluded from this study.Results: This study included 7240 women with systemic lupus erythematosus and 57 920 women without systemic lupus erythematosus as controls. The incidence rate of interstitial cystitis was significantly higher in the systemic lupus erythematosus group, with an incidence rate ratio of 2.26 (95% confidence interval 1.57-3.27, P < 0.0001). After adjustment, the risk increased by 2.45-fold (adjusted hazard ratio 2.45, 95% confidence interval 1.57-3.27, P < 0.05). Age as a factor increases incidence rate ratios among all age groups, 2.12-, 3.32-and 4.65-fold. Age ≥45 years had an increased adjusted hazard ratio (2.07, 95% confidence interval 1.37-3.13, P < 0.05). Comorbidities, for example, hypertension, diabetes mellitus, dyslipidemia and renal disease, were insignificant. Conclusions: This is the first population-based cohort study showing a higher incidence of interstitial cystitis among patients with systemic lupus erythematosus. These findings support the concordance of interstitial cystitis with autoimmune diseases, and the temporal relationship to develop interstitial cystitis in patients with systemic lupus erythematosus.

show abstract

Increased risk of bladder cancer following diagnosis with bladder pain syndrome/interstitial cystitis

Abstract: This investigation detected a novel association between BC and prior IC/BPS.

Cited by 20 publications

References 25 publications

RETRACTED ARTICLE: Inhibition of microRNA-214 promotes epithelial–mesenchymal transition process and induces interstitial cystitis in postmenopausal women by upregulating Mfn2

RETRACTED ARTICLE: Inhibition of microRNA-214 promotes epithelial–mesenchymal transition process and induces interstitial cystitis in postmenopausal women by upregulating Mfn2

Notch controls urothelial integrity in the mouse bladder

Risks of interstitial cystitis among patients with systemic lupus erythematosus: A population‐based cohort study

Contact Info

Product

Resources

About